Announcements Trials
Browse Landscape

Phase

Phase NA 23Phase 2/3 6Phase 1/2 6Phase 2 4Phase 1 3Phase EARLY_PHASE1 1Phase 3 1

Status

Unknown 3Completed 3Recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × Electroporation × Clear all
NCT06378047 2026-02-09

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
2 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02531425 2023-05-15

TNBC

OncoSec Medical Incorporated

Phase 1 Completed
10 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01790451 2015-02-20

Safety and Efficacy of Irreversible Electroporation in Ablation of Prostate Cancer in Humans

Clinical Research Office of the Endourological Society

Phase 1 Completed
16 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡